TrialPloS one2022

Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data.

Caroline S Clarke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.